Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 3 5Phase 1 4Phase NA 1

Status

Unknown 2Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 4

Conditions

Breast Neoplasms 55Neoplasm Metastasis 7Triple Negative Breast Neoplasms 6Ovarian Neoplasms 6Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Advanced Breast Cancer 4Prostatic Neoplasms 3Endometrial Neoplasms 3Carcinoma, Ovarian Epithelial 3Stomach Neoplasms 2Small Cell Lung Carcinoma 2Lymphoma, Non-Hodgkin 2Lymphoma 2Hereditary Sensory and Autonomic Neuropathies 2Colorectal Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Solid Tumor 1Solid Malignancies 1Postmenopausal Women With ER+ HER2- Primary Breast Cancer 1Pancreatic Neoplasms 1Neoplasms by Site 1Mesothelioma, Malignant 1Mesothelioma 1Lung Neoplasms 1Liposarcoma 1Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer 1

Interventions

Fulvestrant 4palbociclib 3Letrozole 3Paclitaxel 2sonidegib 1ribociclib 1irinotecan sucrosofate 1elacestrant 1XMT-1522 1Vorinostat 1Sirolimus 1Ritonavir 1Population Groups 1Itraconazole 1Immunotherapy, Adoptive 1Histone Deacetylase Inhibitors 1FCN-437c 1Docetaxel 1Decitabine 1Dasatinib 1Combined Modality Therapy 1Capecitabine 1CYH33 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × Advanced Breast Cancer × Fulvestrant × Clear all
NCT06941142 2025-04-23

A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 1 Not yet recruiting
382 enrolled
Breast

Advanced Breast Cancer

NCT06047184 2023-09-21

Phase I Study of BEBT-209 in Women With Advanced Breast Cancer

BeBetter Med Inc

Phase 1 Unknown
106 enrolled
Breast

Advanced Breast Cancer

NCT04856371 2021-04-23

Study of CYH33 in Combination With Endocrine Therapy With or Without Palbociclib in Patients With HR+, HER2- Advanced Breast Cancer

Haihe Biopharma Co., Ltd.

Phase 1 Unknown
228 enrolled
Breast

Advanced Breast Cancer

NCT00328120 2010-11-17

Faslodex 500mg Multiple Dose Tolerability Study in BC Patients

AstraZeneca

Phase 1 Completed
20 enrolled
Breast

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡